Synergistic effects of 15-deoxy Δ12,14-prostaglandin J2 on the anti-tumor activity of doxorubicin in renal cell carcinoma

Yasuhiro Yamamotoa, Takehiro Yamamotob, Hiromi Komaa, Ayaka Nishia, Tatsurou Yagamia

a Division of Physiology, Department of Pharmaceutical Health Care, Faculty of Pharmaceutical Sciences, Himeji Dokkyo University, 2-1, kami-ohno 7-Chome, Himeji, Hyogo 670-8524, Japan
b Hyogo Prefectural Kobe High School, 1-5-1 Shironoshita-dori, Nada-ku, Kobe, Hyogo 657-0804, Japan

ARTICLE INFO

Keywords:
Renal cell carcinoma
15-deoxy Δ12,14-prostaglandin J2
Doxorubicin
Phosphoinositide 3-kinase
Chemoresistant

ABSTRACT

An endogenous anticancer agent, 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) induces apoptosis in the chemoresistant renal cell carcinoma (RCC). Peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear receptor for 15d-PGJ2, and mediates the cytotoxicity of 15d-PGJ2 in many cancerous cells. However, 15d-PGJ2 induces apoptosis independently of PPARγ in human RCC cell line such as Caki-2. In the present study, we found that 15d-PGJ2 ameliorated the chemoresistance to one of anthracycline antibiotics, doxorubicin, in Caki-2 cells. Doxorubicin alone exhibited weak cytotoxicity at the concentrations effective for other cancer cells such as Hela cells. In addition, it did not activate caspase 3. However, the cytotoxicity of doxorubicin was increased remarkably and accompanied with the caspase-3 activation in the presence of 15d-PGJ2. Doxorubicin alone damaged plasma membrane, and the combined application of 15d-PGJ2 with doxorubicin increased the membrane permeability slightly. PPARγ was involved in neither the anti-tumor activity nor the synergistic effect of 15d-PGJ2. 15d-PGJ2 induces apoptosis in Caki-2 cells via suppressing the phosphoinositide 3-kinase (PI3K)-Akt pathway. The effect of P13K inhibitor on the cytotoxicity of doxorubicin was additive, but not synergistic. Although the PI3K inhibitor mimicked the cytotoxicity of 15d-PGJ2, it might not be involved in the synergism between 15d-PGJ2 and doxorubicin. In conclusion, 15d-PGJ2 enhanced the chemosensitivity of doxorubicin via the pathway independent of P13K and P13K.

1. Introduction

Renal cell carcinomas (RCCs) account for approximately 2% of adult carcinomas. Despite extensive evaluation of many different treatment modalities, advanced metastatic RCC remains highly resis-
tant to radiotherapy and chemotherapy [1]. Clear cell RCC accounts for the majority of RCC cases [2] and one-third of the patients present with metastases at initial diagnosis. Nearly half of all patients with RCC die within 5 years of diagnosis and 5-year survival for those with metastatic disease is <10% [3]. Chemotherapeutic agents, such as gemcitabine, 5-fluorouracil (5-FU), capecitabine and vinblastine, exhibit clinical benefits partially [4]. Based on the immunogenicity of RCCs, the potency of cytokines, mainly interleukin 2 and/or interferon-α, have been reported by several clinical studies [5,6]. The treatment of RCCs has been modified by chemotherapeutic agents, such as tyrosine kinase inhibitors (sunitinib, sorafenib, pazopanib, and axitinib), the anti-VEGF monoclonal antibody (bevacizumab) administered with interferon α and mammalian target of rapamycin (mTOR) inhibitors (everolimus and temsirolimus) [7]. However, despite these novel therapies, the clinical outcome of patients with RCC remains poor [4].

To overcome the resistance of RCCs to chemotherapy, we have studied combinations of chemotherapy with new agents. Responsiveness of RCCs such as Caki-2 cell for conventional anticancer agents such as 5-FU, camptothecin (CPT) and etoposide (VP16) was lower than that of other types of cancer such as Hela cells [8–12]. CPT and VP16 are inhibitors of DNA topoisoamerase I and II, respectively. DNA topoisoamerasers resolve topological constraints that may arise from DNA strand separation and are therefore important for transcription and replication [13]. Previously, we have reported that 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) enhanced the anti-tumor activity of camptothecin, [11] and etoposide [12]. 15d-PGJ2 is an endogenous anticancer agent. Although peroxisome proliferator-activated receptor-γ (PPARγ) is a nuclear receptor for 15d-PGJ2[14,15], it does not mediate the cytotoxicity of 15d-PGJ2 in RCCs [16,17]. Furthermore, synergistic toxicities of 15d-PGJ2 with topoisoamerasers were also independent from PPARγ.

In cancer, the phosphoinositide 3-kinase (PI3K)/Akt and mTOR pathway is activated via multiple mechanisms [18]. Since the PI3K
signaling is hyperactivated in RCCs, this pathway is one of targeted therapies [19]. 15d-PGJ2 inhibits proliferation of primary astrocytes [20] and neuroblastoma x DRG neuron hybrid cell line N18D3 [21] via down-regulating PI3K-Akt pathway. Previously, we have reported that the PI3K/Akt signaling mediated the cytotoxicity of 15d-PGJ2[17]. Here, we found that a PI3K inhibitor, LY294002, mimicked the cytotoxicity of 15d-PGJ2. Furthermore, 15d-PGJ2 enhanced the anti-tumor activity of the anthracycline antibiotic, doxorubicin, synergistically. In the present study, we ascertained whether the PI3K inhibitor enhanced the anti-tumor activity of doxorubicin.

2. Materials and methods

2.1. Cell lines and cell culture

The Caki-2 human RCC cell line was obtained from Summit Pharmaceuticals International (Tokyo, Japan). The Caki-2 cells were routinely cultured in RPMI-1640 medium supplemented with 10% fetal bovine serum, 50 mg/l penicillin G and 50 mg/l streptomycin (Invitrogen, Tokyo, Japan), at 37 °C in a 5% CO2-95% room air.

2.2. Reagents

15d-PGJ2 was obtained from Cayman Chemicals (Ann Arbor, MI; Cabru, Milan, Italy). Doxorubicin was purchased from Wako Pure Chemical Industries, Ltd. (Osaka, Japan). GW9662 was obtained from Sigma-Aldrich (St. Louis, MO, USA). 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide dye (MTT) and propidium iodide (PI) were purchased from Dojindo Laboratories (Kumamoto, Japan). LY294002 was purchased from Cell Signaling Technology (Boston, MA). The protein concentration was measured using the BCA protein assay reagent obtained from Pierce (Rockford, IL).

2.3. Cell viability analysis

15d-PGJ2 was dissolved in culture medium after evaporation of vehicle. Two different methods were employed for assessment of cell viability as previously reported. First, the MTT reduction assay reflecting mitochondrial succinate dehydrogenase activity was employed. The cells were seeded on a 96-well tissue culture plate at 10,000 cells/cm² and incubated for 24 h prior to drug exposure. The cells were incubated with 15d-PGJ2 and doxorubicin at the indicated concentrations. After 20 h or 24 h, the cells were incubated with MTT solution (0.1 mg/ml in phosphate-buffered saline) for an additional 3 h at 37 °C. The MTT solution was then aspirated off. To dissolve the formazan crystals formed in viable cells, 100 μl dimethyl sulfoxide was added to each well. Absorbance was measured at 570 nm using a spectrophotometer (Mark Microplate Reader, Bio-Rad Laboratories, Hercules, CA, USA). Second, Cell death was also measured by manually counting the percentage of neurons that stained with propidium iodide (PI, 0.1 µg/ml). The cells were seeded on a 24-well tissue culture plate and incubated for 24 h prior to drug exposure. The cells were harvested with lysis buffer [50 mM HEPES (pH 7.4), 5 mM CHAPS and 5 mM DTT]. The reaction buffer, including acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC), a caspase-3 specific substrate, was added to the wells and the production of AMC was sequentially detected with a CytoFluor® Plate reader (MTX Lab Systems, Vienna, VA, USA) at an excitation wavelength of 360 nm and at an emission wavelength of 460 nm. The enzyme activities were determined as initial velocities expressed as nmol AMC/min/ml and were then corrected by the quantity of protein in each well detected by bicinchoninic acid protein assays (Thermo Fisher Scientific, Waltham, MA, USA).

2.4. Fluorimetric assay of caspase-3 activity

Caspase-3 activity was assessed using a Caspase-3 Fluorimetric Assay kit, (Sigma-Aldrich), according to the manufacturer’s instructions. Briefly, the cells were seeded into 96-well plates at a density of 10,000 cells/cm² and incubated with 20 μM 15d-PGJ2 and 1 μM doxorubicin for 24 h. After exposure to the drugs for 24 h, the supernatants were aspirated and the cells were harvested with lysis buffer [50 mM HEPES (pH 7.4), 5 mM CHAPS and 5 mM DTT]. The reaction buffer, including acetyl-Asp-Glu-Val-Asp-7-amido-4-methylcoumarin (Ac-DEVD-AMC), a caspase-3 specific substrate, was added to the wells and the production of AMC was sequentially detected with a CytoFluor® Plate reader (MTX Lab Systems, Vienna, VA, USA) at an excitation wavelength of 360 nm and at an emission wavelength of 460 nm. The enzyme activities were determined as initial velocities expressed as nmol AMC/min/ml and were then corrected by the quantity of protein in each well detected by bicinchoninic acid protein assays (Thermo Fisher Scientific, Waltham, MA, USA).

2.5. Statistical analysis

Data are given as means ± SE (n=numbers of observations). We performed two experiments at least on different days, and confirmed their reproducibility. We analyzed observations obtained on the same day, and presented the typical experimental results among independent ones on different days to minimize experimental errors. Data were statistically analyzed with the Student’s t-test for comparison with the control group. Data on various drugs were statistically analyzed by two-way ANOVA followed by Dunnett’s test for comparison between the groups.

3. Results

3.1. 15d-PGJ2 exacerbated the doxorubicin-disrupted morphology in Caki-2 cells

As shown in Fig. 1, we evaluated cytotoxicities of doxorubicin and 15d-PGJ2 on Caki-2 cells with morphology and MTT-reducing activity (Fig. 1). In control culture, most Caki-2 cells were bipolar. Several cells were multipolar and have protrusions. Caki-2 cells have elongated shapes, and grow attached to a substrate (Fig. 1A). Doxorubicin exhibited weak toxicities at 1 μM alone (Fig. 1B). It decreased bipolar cells and increased polygonal cells (Fig. 1A). 15d-PGJ2 also reduced cell viability slightly at 20 μM alone (Fig. 1B). In contrast to doxorubicin, 15d-PGJ2 kept Caki-2 cells elongated shape, increased protrusions and made focal contacts clear (Fig. 1A). Combination of doxorubicin with 15d-PGJ2 caused cell death markedly (Fig. 1B). In the two anti-cancer agents-treated culture, Caki-2 cells were spherical in shape and peeled in suspension without attaching to a substrate. Filamentous protrusions were extended from residual cells (Fig. 1A).

PPARγ do not mediate the anti-tumor activity of 15d-PGJ2 in Caki-2 cells [11,12,17]. We confirmed that PPARγ antagonist, GW9662, did not rescued Caki-2 cells from the cytotoxicity of 15d-PGJ2 (Fig. 1C). Similarly, GW9662 did not affected viability of Caki-2 cells in doxorubicin-treated Caki-2 cells regardless 15d-PGJ2.

3.2. 15d-PGJ2 and doxorubicin induced apoptosis synergistically in Caki-2 cells

15d-PGJ2-induced apoptosis is accompanied with the caspase activation in Caki-2 cells. We confirmed that 20 μM 15d-PGJ2 activated caspase-3 significantly. On the other hand, 1 μM doxorubicin did not activate caspase-3. However, combination of doxorubicin with 15d-PGJ2 enhanced caspase-3 activity markedly (Fig. 2A).

Apoptosis is also characterized by PI staining of nuclei. PI is membrane impermeable and generally excluded from viable cells. When plasma membrane is damaged, PI is incorporated into cells and as a counterstain in multicolor fluorescent techniques. We have not succeeded in detecting PI-stained nuclei of RCC treated with 1 μM doxorubicin and/or 20 μM 15d-PGJ2 (data not shown). Therefore, we performed PI staining of RCC treated with 5 μM doxorubicin and/or 20 μM 15d-PGJ2 (Fig. 2B and C). Little PI-positive cell was detected in control culture (Fig. 2B and C). PI-positive cells were increased in the doxorubicin-treated culture, but not in the 15d-PGJ2-treated one. Doxorubicin enhanced the PI-staining of 15d-PGJ2-treated cells.
Fig. 1. 15d-PGJ2 exacerbated the doxorubicin-disrupted morphology in Caki-2 cells. Caki-2 was treated with 1 μM doxorubicin (Dox) in the absence or presence of 20 μM 15d-PGJ2 for 24 h. (A) Morphologies were photographed by phase contrast. Scale bar=100 μm. (B) Cell viabilities were determined by MTT reducing activity. (C) Caki-2 cells were treated with 1 μM doxorubicin and/or 20 μM 15d-PGJ2 in the absence (open columns) or presence (filled columns) of 10 μM GW9662. Cell viabilities were determined by MTT reducing activity. Data are expressed as means ± SE. (n = 6). **P < 0.01, compared with control. ##P < 0.01, compared with 15d-PGJ2 alone.

Fig. 2. 15d-PGJ2 and doxorubicin induced apoptosis synergistically in Caki-2 cells. Capase-3: Caki-2 cells were treated with 1 μM doxorubicin in the absence or presence of 20 μM 15d-PGJ2. Caspase-3 activities were determined as initial velocities (A). Data are expressed as means ± SE. (n=3). *P < 0.05, compared with control. **P < 0.01, compared with 15d-PGJ2 alone. PI staining: Caki-2 was treated with 5 μM doxorubicin in the absence or presence of 20 μM 15d-PGJ2 for 24 h. PI-stained Caki-2 cells were photographed (B) and counted (C). Scale bar=100 μm. Cell death is expressed as % (PI-stained cell numbers/total cell numbers). Data are expressed as means ± SE. (n=12). Since PI-stained cells were not detected in the control culture, significant difference compared with the control culture could not be tested.
slightly, but not significant.

3.3. A PI3K inhibitor increased the cytotoxicity of doxorubicin in Caki-2 cells additively

Previously, we have reported that Akt was involved in the cytotoxicity of 15d-PGJ2 [17]. As shown in Fig. 4A, we ascertained whether PI3K was involved in the synergy between 15d-PGJ2 and doxorubicin. The cytotoxicity of doxorubicin and a PI3K inhibitor, LY294002, on Caki-2 cells was evaluated with morphology and MTT-reducing activity. In control culture, most Caki-2 cells were bipolar. Several cells were multipolar and have protrusions. Caki-2 cells have elongated shapes, and grow attached to a substrate (Fig. 3A). The PI3K inhibitor, LY294002, induced cell death in a concentration-dependent manner (Fig. 3B). The PI3K inhibitor, LY294002, reduced the density of Caki-2 cells. In contrast to 15d-PGJ2, LY294002 did not degenerate morphology of Caki-2 cells significantly. In the presence of LY294002, doxorubicin reduced the density of Caki-2 cells and degenerated cell morphology markedly. However, effects of LY294002 on the cytotoxicity of doxorubicin was additive at the indicated concentrations, but not synergistic (Fig. 3A and B).

3.4. Doxorubicin did not condense chromatin in Caki-2 cells

Apoptosis is accompanied with chromatin condensation. As shown in Fig. 4A, 15d-PGJ2 condensed chromatin in RCCs [17] and neurons [22]. Doxorubicin acts the anti-cancer agent via inhibiting topoisomerase II. Previously, we have reported that a topoisomerase I inhibitor, camptothecin, condensed chromatin as well as 15d-PGJ2 [11]. A topoisomerase II inhibitor, etoposide (VP-16), -induced cell death [12] was also accompanied with chromatin condensation in Caki-2 cells (Fig. 4A). Furthermore, 20 µM 15d-PGJ2 increased the etoposide-condensed chromatin markedly. However, doxorubicin did not increase chromatin condensation regardless of 20 µM 15d-PGJ2 under the cytotoxic condition (1 µM, 24 h).

3.5. A PI3K inhibitor increased the cytotoxicity of doxorubicin in Caki-2 cells additively

Previously, we have reported the synergistic effects of 15d-PGJ2 on anti-tumor activities of camptothecin [11] and etoposide [12]. Therefore, we ascertained whether PI3K was involved the synergy
between 15d-PGJ2 and the two topoisomerase inhibitors (Fig. 4B). At the concentration less than 10 μM, LY294002 did not appear to affect the cytotoxicity of camptothecin and etoposide. At the concentration more than 30 μM, the P13K inhibitor enhanced cytotoxicities of the two topoisomerase inhibitors additively, but not synergistically.

4. Discussion

In the present study, we provided the first evidence that 15d-PGJ2 enhanced anti-tumor activities of the anthracycline antibiotic, doxorubicin, in human renal cell carcinoma, Caki-2 cells. Doxorubicin degenerated morphologies of Caki-2 cells in a different fashion from 15d-PGJ2. 15d-PGJ2 targets the cytoskeleton protein, actin, resulting in alteration of cell morphologies [23]. Actin is one of adapter proteins, which mediates the intracellular domain of integrin binds to the cytoskeleton. Since this integrin-adapter protein (actin) -cytoskeleton complex forms the basis of a focal adhesion, it was likely that 15d-PGJ2 increased protrusions and made focal adhesion clear. In contrast to 15d-PGJ2, doxorubicin appeared to enlarge the area of cytosol in comparison with that of nucleus. Doxorubicin altered morphologies of Caki-2 cells similarly to etoposide (VP-16) in accordance with the fact that they are topoisomerase II inhibitors [12].

15d-PGJ2-induced apoptosis was accompanied with chromatin condensation and caspase-3 activation, and restored by co-treatment with a pan-caspase inhibitor, Z-VAD-FMK [17]. In the present study, we confirmed that 15d-PGJ2 activated caspase-3 and induced apoptosis in Caki-2 cells. In addition, 15d-PGJ2 enhanced the doxorubicin-activated caspase-3 synergistically. Doxorubicin has also been reported to condense chromatin in myeloma and leukemia [24]. However, in Caki-2 cells, VP16 caused chromatin condensation, but doxorubicin did not under the condition exhibiting cytotoxicity. Topoisomerase II is the common target for doxorubicin and VP16. However, doxorubicin is the anthracycline antibiotic, whereas VP16 is the alkaloid derived from plants. Because of different basic structures, the two inhibitors did not always exhibit cytotoxicity in the same fashion in Caki-2 cells. To cite another case, doxorubicin elevated the permeability of plasma membrane, but etoposide did not under the condition exhibiting cytotoxicity (data not shown).

In comparison with normal tissues, 15d-PGJ2 are markedly decreased in tumors and metastatic breast tissues, suggesting that the reduction of 15d-PGJ2 affects the development of cancer and its progression to metastasis [25]. 15d-PGJ2 possesses opposite functions, cytoprotective activities and proapoptotic properties in many cancer cell lines [26]. 15d-PGJ2 induces apoptosis PPARγ-dependently in neuroblastoma [27] and hepatic myofibroblasts [28], whereas PPARγ-independently in colorectal cancer [29], breast cancer [30], hepatocellular carcinoma [31] and prostate and bladder carcinoma [32]. We confirmed that PPARγ did not mediate the anti-tumor activity of 15d-PGJ2 in RCCs [11,12,16,17]. In addition, PPARγ antagonist, GW9662, did not suppressed the combined cytotoxicity of 15d-PGJ2 and doxorubicin. These findings suggested that PPARγ did not mediate synergistic effects of 15d-PGJ2 and doxorubicin.

Previously, we have reported that the P13K-Akt signaling played an important role in the cytoprotection and proliferation of RCCs [17]. 15d-PGJ2 markedly decreased the phosphorylation of Akt. The Akt inhibitor showed cytotoxicity with a low IC50 value, suggesting that 15d-PGJ2 exerted cytotoxicity via the inactivation of Akt. In the present study, we confirmed that the P13K inhibitor mimicked the anti-tumor activity of 15d-PGJ2. However, we could not detect the synergistic effect between doxorubicin and P13K inhibitor. In addition, the P13K inhibitor did not enhanced cytotoxicities of another topoisomerase II inhibitor, etoposide, and a topoisomerase inhibitor I, camptothecin. 15d-PGJ2 has been reported to inhibit the ubiquitin-proteasome pathway in neuroblastoma cells [33]. The proteasome inhibitor potentiates the growth inhibition by doxorubicin in leukemia [24]. In Caki-2 cells, we could not rule out the possibility that 15d-PGJ2 might potentiate the anti-proliferative effect of doxorubicin via suppression of the ubiquitin-proteasome pathway. Thus, 15d-PGJ2 increased the chemosensitivity of doxorubicin independently of PPARγ and P13K. Further studies are required to identify targets for 15d-PGJ2, which reduces the chemoresistance of doxorubicin.

Acknowledgement

This study was supported by a Grants-in-Aid for Scientific Research from the Japan Society for the Promotion of Science (grant no. 16K18892). The authors would like to thank Mr. Tsutomu Minami, Mr. Shin-ichi Kusumoto, Mr. Yuta Hyuga, Mr. Shunta Satoi, Miss Michika Kubo, Miss Kaori Tamura, Miss Eri Shimada, Miss Suzuha Tanaka from the Hyogo Prefectural Kobe High School for supporting this study.

Appendix A. Transparency document

Transparency data associated with this article can be found in the online version at http://dx.doi.org/10.1016/j.bbrep.2016.11.004.

References

[1] R.J. Motzer, N.H. Bander, D.M. Nauus, Renal-cell carcinoma, N. Engl. J. Med. 335 (1996) 865–875.
[2] L.J. Costa, H.A. Drabkin, Renal cell carcinoma: new developments in molecular biology and potential for targeted therapies, Oncologist 12 (2007) 1404–1415.
[3] G.H. Mickleish, Gene therapy on renal-cell carcinoma: magic bullet or tragic insanity?, World J. Urol. 13 (1995) 178–185.
[4] R.J. Motzer, P. Russo, Systemic therapy for renal cell carcinoma, J. Urol. 163 (2000) 408–417.
[5] Y. Aso, H. Tazaki, T. Umeda, K. Marumo, Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. Recombinant Human Interleukin-2 (S-6820) Research Group on Renal Cell Carcinoma, Prog. Clin. Biol. Res. 303 (1989) 681–688.
[6] T. Hayashi, Y. Miyagawa, A. Tsujimura, N. Nonomura, M. Minami, A. Okuyama, A case of renal cell carcinoma with multiple lung metastases refractory to interferon-alpha showing complete remission by interleukin-2 monotherapy, Int. J. Urol. 13 (2006) 805–808.
[7] M. Buzek, B. Escudier, E. Bartnik, C. Szzyryk, A. Czarnecka, Resistance to tyrosine kinase inhibitors in clear cell renal cell carcinoma: from the patient’s head to molecular mechanisms, Biochim. Biophys. Acta 1845 (2014) 31–41.
[8] N. Pessah, M. Reznik, M. Shams, F. Yantiri, H. Xin, K. Bowdish, N. Shomron, G. Ast, D. Shahat, Bioactivation of carbamate-based 20S5-camptothecin produgs, Bioorg Med. Chem. 12 (2004) 1859–1866.
[9] J. Schep, M. Guerra-Rebello, G. Sancilinico, A. Moure, I. Masip, D. Gonzalez-Ruiz, N. Rubio, B. Crousas, O. Mea-Cortes, N. Londoni, V. Plans, A. Morreale, J. Blanco, A.R. Ortiz, A. Messeguer, T.M. Thompson, Protein-protein interaction antagonists as novel inhibitors of non-canonical polyubiquitylation, PloS One 5 (2010) e11403.
[10] K. Takara, S. Horibe, Y. Oba, E. Yoshikawa, N. Oshinski, T. Yokoyama, Effects of 19 herbal extracts on the sensitivity to paclitaxel or 5-fluorouracil in HeLa cells, Biol. Pharm. Bull. 28 (2005) 138–142.
[11] Y. Yamamoto, M. Fujita, H. Koma, M. Yamamori, T. Nakamura, N. Okamura, T. Yamagi, 15-Deoxy-Delta12,14-prostaglandin J2 enhanced the anti-tumor activity of camptothecin against renal cell carcinoma independently of toposisomerase-II and PPARgamma pathways, Biochem. Biophys. Res. Commun. 410 (2011) 563–567.
[12] Y. Yamamoto, H. Koma, H. Hiramatsu, M. Abe, K. Murakami, A. Ohya, T. Yamagi, Treatment of etoposide combined with 15-deoxy-Delta-prostaglandin J exerted synergistic antitumor effects against renal cell carcinoma via peroxisome proliferator-activated receptor-gamma-independent pathways, Mol. Clin. Oncol. 2 (2014) 292–296.
[13] Y. Poznanski, E. Leo, H. Zhang, C. Marchand, DNA topoisomerases and their poisoning by anticancer and antibacterial drugs, Chem. Biol. 17 (2010) 421–433.
[14] S.A. Kliwer, J.M. Lenhardt, T.M. Willson, I. Patel, D.C. Morris, J.M. Lehmann, A prostaglandin J2 metabolite binds peroxisome proliferator-activated receptor gamma and promotes adipocyte differentiation, Cell 83 (1995) 815–819.
[15] B.M. Forman, P. Tontonoz, J. Chen, F.P. Brun, B.M. Spiegelman, R.M. Evans, 15-Deoxy-Delta12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma, Cell 83 (1995) 803–812.
[16] M. Fujita, T. Yamagi, M. Fujii, C. Tohji, K. Takase, Y. Yamamoto, K. Sawada, M. Yamamori, N. Okamura, Cytotoxicity of troglitazone through PPARgamma-independent pathway and p38 MAPK pathway in renal cell carcinoma, Cancer Lett. 312 (2011) 219–227.
[17] M. Fujita, C. Tohji, Y. Honda, Y. Yamamoto, T. Nakamura, T. Yamagi, M. Yamamori, N. Okamura, Cytotoxicity of 15-deoxy-Delta[12,14]-prostaglandin J(2) through PPARgamma-independent pathway and the involvement of the JNK and Akt pathway in renal cell carcinoma, Int. J. Med. Sci. 9 (2012) 555–566.
K. Podsypanina, L.H. Ellenson, A. Nemes, J. Gu, M. Tamura, K.M. Yamada, C. Cordon-Cardo, G. Catoretti, P.E. Fisher, R. Parsons, Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems, Proc. Natl. Acad. Sci. USA 96 (1999) 1563–1568.

C. Sourbier, V. Lindner, H. Lang, A. Agouni, E. Schordan, S. Danilin, S. Rothhut, D. Jacqmin, J.J. Helwig, T. Massfelder, The phosphoinositide 3-kinase/Akt pathway: a new target in human renal cell carcinoma therapy, Cancer Res. 66 (2006) 5130–5142.

S. Giri, R. Rattan, A.K. Singh, I. Singh, The 15-deoxy-delta12,14-prostaglandin J2 inhibits the inflammatory response in primary rat astrocytes via down-regulating multiple steps in phosphatidylinositol 3-kinase-Akt-NF-kappaB-p300 pathway independent of peroxisome proliferator-activated receptor gamma, J. Immunol. 173 (2004) 5196–5208.

S.H. Koh, B. Jung, C.W. Song, Y. Kim, Y.S. Kim, S.H. Kim, 15-Deoxy-delta12,14-prostaglandin J2, a neuroprotectant or a neurotoxicant?, Toxicology 216 (2005) 232–243.

T. Yagami, K. Ueda, K. Asakura, N. Takasu, T. Sakaeda, N. Itoh, G. Sakaguchi, J. Kishino, H. Nakazato, Y. Katsuyama, T. Nagasaki, Y. Hori, K. Hanasaki, A. Arimura, M. Fujimoto, Novel binding sites of 15-deoxy-Delta12,14-prostaglandin J2 in plasma membranes from primary rat cortical neurons, Exp. Cell Res. 291 (2003) 212–227.

G. Aldini, M. Carini, G. Vistoli, T. Shibata, C.W. Song, Y. Kim, Y.S. Kim, S.H. Kim, 15-Deoxy-delta12,14-prostaglandin J2 in plasma membranes from primary rat cortical neurons, Exp. Cell Res. 291 (2003) 212–227.

L. Li, J. Tao, J. Davaille, C. Feral, A. Mallat, J. Riusset, H. Vidal, S. Lotersztajn, 15-deoxy-Delta 12,14-prostaglandin J2 inhibits apoptosis of human hepatic myofibroblasts. A pathway involving oxidative stress independently of peroxisome proliferator-activated receptors, J. Biol. Chem. 276 (2001) 38152–38158.

K.L. Scharfer, H. Takahashi, V.M. Morales, G. Harris, S. Barton, E. Osawa, A. Nakajima, L.J. Saubermann, PPARGamma inhibitors reduce tubulin protein levels by a PPARgamma, PPARdelta and proteasome-independent mechanism, resulting in cell cycle arrest, apoptosis and reduced metastasis of colorectal carcinoma cells, Int. J. Cancer 120 (2007) 702–713.

C.E. Clay, A. Monjazeb, J. Thorburn, F.H. Chilton, K.P. High, 15-Deoxy-Delta12,14-prostaglandin J2-induced apoptosis does not require PPARGamma in breast cancer cells, J. Lipid Res. 43 (2002) 1818–1828.

H. Okano, K. Shiraki, H. Inoue, Y. Yamanaka, T. Kawakita, Y. Saitou, Y. Yamaguchi, N. Endoimura, N. Yamamoto, K. Sugimoto, K. Murata, T. Nakano, 15-deoxy-delta-12-14-PGJ2 regulates apoptosis induction and nuclear factor-kappaB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepatocellular carcinoma, Lab. Invest. 83 (2003) 1529–1539.

C.L. Chaffer, D.M. Thomas, E.W. Thompson, E.D. Williams, PPARGamma-inde- pendent induction of growth arrest and apoptosis in prostate and bladder carcinoma, BMC Cancer 6 (2006) 53.

Z. Wang, V.M. Aris, K.D. Ogburn, P. Soteropoulos, M.E. Figueiredo-Pereira, Prostaglandin J2 alters pro-survival and pro-death gene expression patterns and 26 S proteasome assembly in human neuroblastoma cells, J. Biol. Chem. 281 (2006) 21377–21386.